The aim of the present study was to explore the level of risk associated with community use of non-steroidal anti-inflammatory drugs (NSAIDs). Methods We carried out a matched case-control study of the relationship between recent use of NSAIDs and the presence of functional renal impairment present at the time of hospitalisation with a range of clinical problems. Cases (n=110) were consecutive patients admitted acutely to hospital who had serum creatinine levels greater than or equal to 0.15 mmol l −1 , which improved by 20% or more within the next 14 days, or prior to discharge from hospital. Controls (n=189) were subjects of the same sex and age (to within 5 years) as the cases, who were admitted to the same hospital, who had normal serum creatinine levels (<0.12 mmol l −1 ) throughout their hospital stay. Information on a number of study factors, including recent use of aspirin and other NSAIDs, was obtained by structured interview. Results Overall, there was a weak association between consumption of NSAIDs (including non-prophylactic aspirin) and the development of functional renal impairment-adjusted odds ratios (OR) with use of NSAIDs in the previous week or in the previous month: OR 1.5 (95% CI 0.80, 2.9) and 1.8 (95% CI 0.97, 3.4) respectively. In subjects with a previous history of renal disease the adjusted OR was 6.6 (0.75, 57.8) and in those with a history of gout or hyperuricaemia the OR was 7.2 (1.3, 40.2). There was a weak positive relationship between the dose of drug consumed in the previous week and the odds of functional renal impairment. The relationship between risk and published figures for drug half-lives (t D ) was stronger. The odds ratio increased from 1.2 (95% CI 0.61, 2.4) with a t D ≤4 h, to 4.8 (1.5, 15.8) with a t D of ≤12 h ( P=0.012, test for trend). This relationship remained statistically significant after adjustment for a number of clinical variables and the dose of drug ingested. Conclusions NSAIDs are an important cause of functional renal impairment in subjects with renal disease or a history of gout or hyperuricemia. The half-life of the drug is more important than the ingested dose in determining the risk of this outcome. Long half-life drugs should be avoided in individuals who are at risk of developing renal impairment.
Introduction prostaglandins by the kidney and the loss of their vasodilator actions results in renal vasoconstriction [1, 3] . Non-steroidal anti-inflammatory drugs (NSAIDs) are a well known cause of renal failure. A number of renal syndromes
Although the physiological features of this syndrome have been extensively investigated in experimental studies there have been described, but the most common is functional renal impairment of vascular origin [1] . Renal ischaemia is have been few controlled epidemiological investigations of renal disorders associated with NSAIDs [4] [5] [6] [7] [8] [9] . Despite believed to be a consequence of the unopposed actions on the renal vasculature of the vasoconstrictor hormones widespread concern regarding the risks of these drugs in the elderly they continue to be widely used, so even low relative angiotensin, noradrenaline and arginine vasopressin in patients who are physiologically 'stressed' as a result of risks of renal dysfunction could translate into a substantial burden of disease. The epidemiological studies that have serious underlying renal, hepatic, metabolic or cardiac disorders [2] . In these clinical states renal prostaglandins help been performed have tended to concentrate on chronic renal failure, or have relied on diagnoses of renal pathology to define cases for investigation [4] . There has been only renal impairment [7, 8] . Most attempts to define risk factors Information gathering for the development of renal impairment with NSAIDs have been uncontrolled case series and spurious associations
The index day for cases and controls was the day of admission to hospital. Information on all drugs that had are likely.
In the present study we used case-control methodology been used prior to the index day, past medical history (in particular prior diagnosis of renal disease, hypertension, to explore the level of risk associated with community use of NSAIDs. We were interested in the clinical predisposing cardiovascular disorders, hepatic disease and musculoskeletal disorders), demographic details, alcohol consumption and factors, and also wished to know to what extent the risk increased with the dose and the half-life of drugs that had smoking history were obtained by structured interview. All interviews were conducted within 1 week of admission to been consumed prior to development of renal impairment.
hospital, and the great majority were within 4 days. The interviewers knew whether a subject was a case or control, but understood the importance of adhering strictly to the Methods wording of the questionnaire. Each question could be We carried out a matched case-control study of the repeated only once for clarification. We were particularly relationship between recent use of NSAIDs and transient interested in the consumption of analgesic and antirenal impairment. The study was based in two general inflammatory medications. This information was obtained hospitals in the Hunter Region of New South Wales-the by a series of open questions enquiring about any drugs John Hunter Hospital and Newcastle Mater Hospital. These used for painful complaints. These were followed by more hospitals provide most of the acute care for a population of direct questions and presentation of 'flash' cards, listing in around 450 000. The study was approved by the ethics large type the proprietary and trade names of all relevant committees of the University of Newcastle and the Hunter products on the Australian market. General practitioners Area Health Service, and all participants gave their informed attended by cases and controls were contacted to confirm consent. This study was run in parallel with a case-control the information on prescribed drug use obtained by study designed to explore the relationship between use of interview. These methods had been used previously in a NSAIDs and the development of congestive heart failure. study of major gastrointestinal complications of NSAID treatment. In addition to the information obtained by interview we abstracted the following details from medical Case definition records and hospital computerised records: haematological and additional biochemical data, clinical notes regarding We consulted renal physicians in the Newcastle area and previous medical history and the primary diagnosis thought reached agreement on the following definition of functional to be responsible for the hospital admission. renal impairment: cases were consecutive patients admitted acutely to the study hospitals who had serum creatinine Statistical analysis levels greater than or equal to 0.15 mmol l −1 , which improved by 20% or more within the next 14 days, or prior
The anticipated prevalence of NSAIDs use in the controls to discharge from hospital, whichever came first.
was 20% [11] . We aimed to recruit 170 cases and 340 controls to detect an overall odds ratio (OR) of 2 associated with the use of NSAIDs with a power of 90% and type 1 Case recruitment error of 0.05 [12] . The odds ratio was assumed to be a valid estimate of the relative risk. Non-use of NSAIDs and aspirin We identified cases through computerised records containing was the reference for calculation of exposure odds ratios. routine biochemical investigations that are maintained by Conditional logistic regression was used to calculate crude the Hunter Area Pathology Service. Three times weekly and adjusted odds ratios and their 95% confidence intervals. records were loaded into a relational database, which created
The mean daily dose of NSAIDs in the week prior to a time series of plasma creatinine values for every patient admission was used to assess dose response. This dose was admitted to the study hospitals. Potential cases were standardised by using the manufacturer's recommended identified through the data-base. Patients who were initially minimum daily maintenance dose for rheumatoid arthritis too sick to be interviewed were followed up. If they as one dose unit [11, 13] . The dose calculation excluded remained unfit for interview their details were excluded regular low-dose aspirin (regular daily dose of 100 to from final analysis. 300 mg) as this was likely to have been taken as prophylaxis against cardiovascular events, which were found to be associated with the study outcome. Published plasma halfSelection and recruitment of controls life values for the drugs taken by subjects in the study were obtained from reference sources [14] . For the purpose We tried to match two controls to each case. Controls were subjects of the same sex and age (to within 5 years) as the of analysis drugs were categorised as short half-life <4 h (commonly used examples: ibuprofen, diclofenac, aspirin), cases, who were admitted to the same hospital, who had normal serum creatinine levels (<0.12 mmol l −1 ) through-4-11.9 h (indomethacin, sulindac, ketoprofen SR), and ≥12 h (naproxen, piroxicam, tenoxicam). out their hospital stay. Controls were identified from the same data-base as the cases and the same exclusion criteria
We used multiple conditional logistic regression analysis to adjust for all variables that were statistically significantly were applied. associated with renal impairment if their inclusion in the disturbances (10% of cases, 0% of controls), gastrointestinal disease (16% of cases and 10% of controls), fractures/trauma model affected the magnitude of the coefficients [15] . Multiple conditional logistic regression was used to assess (18% of cases and 8% of controls) and neurological and psychiatric disorders (9% of cases and 4% of controls). interactions and relationships between drug doses and published plasma half-life values. The statistical computer
The median plasma creatinine concentration on admission was 0.19 mmol l −1 in cases, compared with 0.09 mmol l −1
package Stata (version 4.0) was used to analyse the data. All P values were two sided. in controls. The corresponding values for plasma urea concentrations were 18.4 mmol l −1 in cases and 6.3 mmol l −1 in controls. The average fall in plasma Results creatinine in the cases was 0.06 mmol l −1 (32% of the mean admission concentration). In comparison the average fall in Of the 164 cases of functional renal impairment identified, we were only able to use the data from 110. The remaining plasma creatinine in the controls was 0.01 mmol l −1 (11% of the mean admission concentration). Blood urea concen-54 were either too unwell to be interviewed or died soon after admission. Comparison of included and excluded cases trations were approximately three times higher in cases than in control patients. Sodium and potassium levels were showed that the latter were on average 2.6 years older. The sex distributions were similar and there were no significant quite similar. differences in blood creatinine, urea and electrolyte levels (data not shown).
Drug consumption by cases and controls
There was a higher use of drugs for cardiovascular disorders Characteristics of cases and controls by cases than by control subjects ( Table 2 ). The differences were modest in the cases of calcium channel blocking drugs Table 1 shows the characteristics of cases and controls. Despite matching the cases were slightly older than the and b-adrenoceptor blockers. It is likely that these differences reflect the high prevalence of cardiovascular disorders controls, and subsequent analyses adjusted for this age difference. Cases were more likely than controls to have a amongst the cases. The differences were substantial in the case of ACE inhibitors and high ceiling diuretics. This past history of malignancy, hypertension, heart disease, renal/urinary tract disease and gout/hyperuricemia.
probably indicates a causal association between these agents and functional renal impairment. However the study was Primary reasons for admission to hospital differed between the groups. Renal and urinary tract diagnoses were mennot designed to explore these relationships in detail. tioned in 23% of cases compared with 3% of controls. Differences also existed for electrolyte and acid base
Use of non-steroidal anti-inflammatory drugs
Cases were more likely to have been taking prophylactic controls and the unadjusted odds ratio with use in the week subgroups. However the data suggest that these disorders are risk factors for the development renal impairment after prior to hospitalisation was approximately 2.
Inclusion of a number of variables resulted in a statistically ingestion of NSAIDs. significant improvement in the fit of the statistical model, as judged by changes in deviance. The variables were: a previous history of heart disease, renal disease and gout/ Dose-reponse relationship hyperuricaemia. Age was also included in the model because it remained an important determinant of the odds of renal There was evidence of a positive relationship between the dose of drug and the odds of functional renal impairment impairment despite matching.
Adjustment resulted in a decrease in the odds ratios with (P=0.054; Table 5 ). However the slope was not steep and the relationship was not statistically significant after adjusting use of NSAIDs in the last week or month (Table 3) . Use of non-aspirin NSAIDs, or any NSAIDs (including nonfor age and a previous history of cardiac disease. Examination of dose-response relationships in sub-groups was hampered prophylactic aspirin), was associated with an approximate 1.5 times increase in the odds of developing reversible renal by small numbers, but the relationship approached statistical significance in the case of subjects with gout/hyperuricaemia. impairment. However this was not statistically significant at the 5% level.
The relationship to half life of NSAIDs Investigation of risk factors
Possible effect modification by a history of renal disease,
The odds ratio tended to increase with the half-life of the non-steroidal anti-inflammatory drug used in the week prior heart disease, gout/hyperuricaemia, chronic liver disease, age and sex, were explored by including interaction terms to admission (Table 6 ). The test for log-linear trend was statistically significant in the univariate analysis ( P=0.012). into the multiple regression model. There was evidence of a statistically significant interaction only with a history of We simultaneously adjusted these analyses for dose by entering this as a continuous variable, and the relationship gout/hyperuricemia (x 2 1df =6.72, P=0.010), and with a history of renal disease (x 2 1df =5. 35, P=0.021) .
between drug half-life and the odds ratio remained statistically significant (test for log linear trend, p=0.032). In contrast, Table 4 shows the odds ratios associated with the use of NSAIDs in subgroups of patients with gout/hyperuricaemia when half-life was entered as a continuous variable the relationship between dose and the odds ratio for renal and renal disease. Note that the confidence intervals are wide due to the small number of patients in the various impairment was non-significant (Table 5) . *Adjusted odds ratios were calculated from conditional logistic regression models. Adjustment was made for a previous history of heart disease and age in years. Table 5 The relationship between the odds of functional renal impairment and the average daily dose of NSAIDs used in the week prior to admission (in standard dose units). diabetes may be important but may have been missed in the Discussion study because of inadequate statistical power. The result of our unadjusted analysis for exposure to The main findings of this study were that there was a weak overall association between recent use of NSAIDs and NSAIDs in the past month (OR 2.5, 95% CI 1.4, 4.4) was similar to that recorded by Evans et al. using the Tayside development of functional renal impairment but two risk factors-a previous history of renal disease or a previous record-linkage system: OR for exposure in the past 90 days 2.2 (1.5, 3.3) [7] . However in our study adjustment for history of gout/hyperuricaemia-were important independent risk factors. The dose of drug was not an important confounding weakened the association. Evans et al. relied on recorded prescriptions rather than reported consumption determinant of the outcome in this study, but there was a strong relationship between the half-life value for the drug of NSAIDs and collected no information directly on clinical factors that were potential confounders. and the risk of developing functional renal impairment. This relationship persisted after adjustment for ingested dose.
We found only a weak relationship between the ingested dose of NSAIDs and the risk of development of renal The overall results of this study may appear to conflict with confident assertions regarding a high level of risk of impairment. This contrasts with the stronger relationship found by Perez Gutthan et al. [8] . In a case-control study renal impairment induced by NSAIDs [5] . It is important to consider a number of factors that may explain this apparent involving 28 subjects with more severe degrees of renal impairment these workers found an odds ratio for developdiscrepancy. First, most of the literature on this topic has been uncontrolled. As use of NSAIDs is extremely common ment of renal failure of 9.8 with high doses. Exploring dosage in epidemiological studies of NSAIDs is difficult in most communities, spurious associations with individual cases of renal impairment are likely. In this situation because of the varying potencies of the different drugs. In this study we used a dose standardisation approach that has controlled studies are necessary to provide unconfounded estimates of the strength of the association. In this study, been used by others, and also by us in previous work [11, 13] . This is an arbitrary standardisation that may tend to most of the risk appeared to be concentrated in identifiable subgroups, particularly those with a prior history of renal obscure true dose response relationships. However, using this approach we have been able to show a fairly strong disease or gout. In such subjects, the estimated relative risks were high and would translate into a substantial excess risk.
relationship between the ingested dose and the development of major gastrointestinal complications [11] . The weak doseBecause we have not highlighted other risk factors in this study it should not be assumed they do not exist. We set response seen in the present study may be due to the narrow range of doses that had been ingested in the week prior to fairly strict statistical criteria when examining the results for interactions. Other factors such as cardiac disease and admission to hospital. Few subjects had a daily dose in excess of one standard unit and this contrasts with the This study was supported by a grant from the National Health and Medical Research Council of Australia and from findings of a previous study we conducted of gastrointestinal complications [11] . However, it should be noted that the Pfizer Pharmaceuticals (Australia) Pty Limited. dose effect disappeared entirely after simultaneous adjustment for drug half-life, and we believe that the latter is a more References important determinant of the risk of renal impairment The present study does not allow us to explain the 563-572. apparently strong relationship between drug half-life and 2 Blackshear JL, Napier JS, Davidman M, Stillman MT. Renal risk. However, it was not due to confounding by dose as it complications of non-steroidal anti-inflammatory drugs: remained after simultaneous adjustment for the latter. Also, identification and monitoring of those at risk. Sem Arth it was not due to confounding by the presence of the risk Rheumat 1985; 14: 163-175. factors that were examined in this study. In our view, the clinical significance. An effect of this is that differences
